---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-006446"
form_type: "8-K"
ticker: "ARMP"
cik: "0000921114"
company_name: "Armata Pharmaceuticals, Inc."
filed_at: "2026-01-26T23:59:59+00:00"
generated_at: "2026-05-16T08:19:20.147520+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Armata extends credit maturity to June 2027 and warrants to Jan 2031 with Innoviva affiliate

## Summary
- Maturity of four credit agreements with Innoviva Sub extended to June 1, 2027.
- Expiration of four warrants to purchase ~10.65M shares extended to January 26, 2031.
- Voting agreement termination date extended to earlier of Jan 2031 or FDA approval of any product candidate.

## SEC filing metadata
- accession: 0001104659-26-006446
- form_type: 8-K
- ticker: ARMP
- cik: 0000921114
- company_name: Armata Pharmaceuticals, Inc.
- filed_at: 2026-01-26T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921114/000110465926006446/0001104659-26-006446-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921114/000110465926006446/tm263967d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-006446
- JSON: https://secwatch.observer/filing/0001104659-26-006446.json
- Plain text: https://secwatch.observer/filing/0001104659-26-006446.txt

## Key facts
- Material Agreements
  Armata Pharmaceuticals, Inc. amended Voting Agreement Amendment with Innoviva, Inc. and Innoviva Strategic Opportunities LLC (effective 2026-01-23).
  - Action: amendment
  - Counterparty: Innoviva, Inc. and Innoviva Strategic Opportunities LLC
  - Effective: 2026-01-23
  source text: On January 23, 2026, the Company, Innoviva and Innoviva Sub entered into an amendment (the “Voting Agreement Amendment”) to that certain Second Amended and Restated Voting Agreement, dated February 9, 2022, by and among the Company, Innoviva and Innoviva Sub
  evidence_url: https://www.sec.gov/Archives/edgar/data/921114/000110465926006446/0001104659-26-006446-index.htm
- Material Agreements
  Armata Pharmaceuticals, Inc. amended Credit Agreement Amendments with Innoviva Strategic Opportunities LLC (effective 2026-01-23).
  - Action: amendment
  - Agreement: credit facility
  - Counterparty: Innoviva Strategic Opportunities LLC
  - Effective: 2026-01-23
  source text: On January 23, 2026, Armata Pharmaceuticals, Inc. (the “Company”) entered into amendments (collectively, the “Credit Agreement Amendments”) to four existing credit agreements, each as previously amended, with Innoviva Strategic Opportunities LLC (“Innoviva Sub”), a wholly owned subsidiary of Innoviva, Inc., a principal shareholder of the Company (“Innoviva”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/921114/000110465926006446/0001104659-26-006446-index.htm
- Material Agreements
  Armata Pharmaceuticals, Inc. amended Warrant Amendment with Innoviva Strategic Opportunities LLC (effective 2026-01-23).
  - Action: amendment
  - Counterparty: Innoviva Strategic Opportunities LLC
  - Effective: 2026-01-23
  source text: On January 23, 2026, the Company and Innoviva Sub entered into an amendment (the “Warrant Amendment”) to four outstanding warrant certificates previously issued by the Company to Innoviva Sub.
  evidence_url: https://www.sec.gov/Archives/edgar/data/921114/000110465926006446/0001104659-26-006446-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.